Buprenorphine Pharmacology Related to Addiction Treatment - 18

This study has been completed.

Sponsors and Collaborators:	National Institute on Drug Abuse (NIDA) University of Vermont
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000236

Purpose

The purpose of this study is to examine the interactions between buprenorphine and naltrexone, and to assess how they may directly impact the clinical issues involving: transferring patients from buprenorphine to naltrexone, developing a non-abusable form of buprenorphine, and enhancing patient acceptability of naltrexone.

Condition	Intervention	Phase
Opioid-Related Disorders	Drug: Buprenorphine/naloxone	Phase II

Drug Information available for: Naloxone Naloxone hydrochloride Buprenorphine Buprenorphine hydrochloride

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment
Official Title:	Buprenorphine Pharmacology Related to Addiction Treatment

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Drug use
Opioid agonist effects
Opiate withdrawal
Psychological changes in: pupil diameter, blood pressure, heart rate, respiration

Estimated Enrollment:

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Please contact site for information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000236

Locations

United States, Vermont
Treatment Research Center
Burlington, Vermont, United States, 05401

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

University of Vermont

Investigators

Principal Investigator:

Warren Bickel, Ph.D.

University of Vermont

More Information

Study ID Numbers:	NIDA-06969-18, R01-06969-18
Study First Received:	September 20, 1999
Last Updated:	August 16, 2005
ClinicalTrials.gov Identifier:	NCT00000236
Health Authority:	United States: Federal Government

Study placed in the following topic categories:

Buprenorphine
Behavior, Addictive
Mental Disorders
Substance-Related Disorders

Disorders of Environmental Origin
Opioid-Related Disorders
Naloxone

Additional relevant MeSH terms:

Sensory System Agents
Therapeutic Uses
Narcotic Antagonists
Physiological Effects of Drugs
Central Nervous System Depressants
Narcotics

Peripheral Nervous System Agents
Analgesics
Central Nervous System Agents
Pharmacologic Actions
Analgesics, Opioid

ClinicalTrials.gov processed this record on January 15, 2009